The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Adverse effects of ramucirumab plus paclitaxel for HER2- G/GEJ cancer
Giovanni Randon, MD, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano, Milan, Italy, reflects on the ARMANI trial (NCT02934464), which investigated ramucirumab plus paclitaxel or CAPOX/FOLFOX followed by fluoropyrimidine monotherapy as switch maintenance or early second-line therapies in HER2-negative (HER2-) gastric/gastroesophageal junction (G/GEJ) cancer. Whilst the rate of grade 3 adverse effects (AE) doubled in the ramucirumab arm, the rate of neurotoxicity was not increased. Overall, there was a consistent safety profile of paclitaxel plus ramucirumab, making it suitable to progress into further studies. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
